Status
Conditions
Treatments
About
The purpose of this study is to (1) investigate the effect of known dystonia-causing mutations on brain structure and function, to (2) identify structural brain changes that differ between clinical phenotypes of dystonia, and to (3) collect DNA, detailed family history, and clinical phenotypes from patients with idiopathic dystonia with the goal of identifying new dystonia-related genes. Investigators will be recruiting both healthy control subjects and subjects with any form of dystonia. For this study there will be a maximum of two study visit involving a clinical assessment, collection of medical and family history, task training session, an MRI using the learned tasks, and finally a blood draw for genetic analysis. In total, these visits will take 3-5 hours. If the dystonia subjects receive botulinum toxin injections for treatment, the participants and their matched controls will be asked to come for a second visit.
Full description
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
General Exclusion (both Dystonia and Control groups):
Inclusion Criteria:
Previous diagnosis of dystonia which include but is not limited to:
cervical dystonia (50 subjects)
blepharospasm (25 subjects)
limb dystonia (50 subjects)
spasmodic dysphonia (25 subjects)
segmental dystonia
multi-focal dystonia
Any childhood-onset dystonia (25 subjects) Age > 11 years
No prior dystonia diagnosis (175 subjects) Age > 11 years
Exclusion Criteria:
Control group:
History of or current neurological or psychiatric diagnosis - depression and/or anxiety accepted, but must not be in active phase Current use of any neuroactive medication, SSRI/medication for depression and/or anxiety accepted
200 participants in 2 patient groups
Loading...
Central trial contact
Jeff Waugh, MD, PhD; Alyssa Boudreau
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal